SSA
URGN icon

Sierra Summit Advisors’s UroGen Pharma URGN Stock Holding History

Sierra Summit Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,515
Closed -$218K – 220
2023
Q4 		$218K Buy
+14,515
New +$188K 0.06% 181

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Sierra Summit Advisors's URGN Position: Q1 2024 in Review

Sierra Summit Advisors sold out of UroGen Pharma (URGN) in Q1 2024, closing a stake of 14,515 shares — an estimated $218K sold.

Sierra Summit Advisors first reported a position in URGN in Q4 2023 and held it in 1 quarter. The position peaked at $218K in Q4 2023. 112 funds tracked by Wall St. Rank hold URGN as of Q1 2024.

  • Sierra Summit Advisors reported no remaining UroGen Pharma position as of Q1 2024 after selling out during the quarter.
  • Sierra Summit Advisors sold 14,515 UroGen Pharma shares in Q1 2024, an estimated $218K.
  • Sierra Summit Advisors first reported a position in UroGen Pharma in Q4 2023 and held it in 1 quarter.
  • Sierra Summit Advisors's UroGen Pharma position peaked at $218K in Q4 2023.
  • 112 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2024.

Based on Sierra Summit Advisors's 13F filing for Q1 2024, filed 9 May 2024.